Avasimibe Pfizer.
Avasimibe (also known as CI-1011 or PD-148515) is a selective acyl-coenzyme A:cholesterol O-acyltransferase (ACAT) inhibitory lipid-regulating agent under development by Pfizer (formerly Parke-Davis) for the potential treatment of hyperlipidemia and atherosclerosis. The compound is currently undergoing phase III clinical trials [371470].
Burnett
John R
JR
Department of Core Clinical Pathology & Biochemistry, Division of Laboratory Medicine, Royal Perth Hospital, Wellington Street, Perth, WA 6847, Australia. john.burnett@health.wa.gov.au
Huff
Murray W
MW
D000081:Acetamides; D000085:Acetates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000201:enzymology; D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000201:enzymology; D013449:Sulfonamides; D013451:Sulfonic Acids / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*
D000081:Acetamides; D000085:Acetates; D004791:Enzyme Inhibitors; D013449:Sulfonamides; D013451:Sulfonic Acids; C423185:avasimibe